Literature DB >> 16894219

Fluorescence and solution NMR study of the active site of a 160-kDa group II intron ribozyme.

Orlando H Gumbs1, Richard A Padgett, Kwaku T Dayie.   

Abstract

We have reconstructed the group II intron from Pylaiella littoralis (PL) into a hydrolytic ribozyme, comprising domains 1-3 (D123) connected in cis plus domain 5 (D5) supplied in trans that efficiently cleaves spliced exon substrates. Using a novel gel-based fluorescence assay and nuclear magnetic resonance (NMR) spectroscopy, we monitored the direct binding of D5 to D123, characterized the kinetics of the spliced exon hydrolysis reaction (which is mechanistically analogous to the reverse of the second catalytic step of splicing), and identified the binding surface of D123 on D5. This PL ribozyme acts as an RNA endonuclease even at low monovalent (100 mM KCl) and divalent ion concentrations (1-10 mM MgCl(2)). This is in contrast to other group II intron ribozyme systems that require high levels of salt, making NMR analysis problematic. D5 binds tightly to D123 with a K(d) of 650 +/- 250 nM, a K(m) of approximately 300 nM, and a K(cat) of 0.02 min(-1) under single turnover conditions. Within the approximately 160-kDa D123-D5 binary complex, site-specific binding to D123 leads to dramatic chemical shift perturbation of residues localized to the tetraloop and internal bulge within D5, suggesting a structural switch model for D5-assisted splicing. This minimal ribozyme thus recapitulates the essential features of the reverse of the second catalytic step and represents a well-behaved system for ongoing high-resolution structural work to complement folding and catalytic functional studies.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16894219      PMCID: PMC1557703          DOI: 10.1261/rna.137006

Source DB:  PubMed          Journal:  RNA        ISSN: 1355-8382            Impact factor:   4.942


  84 in total

1.  A catalytically active group II intron domain 5 can function in the U12-dependent spliceosome.

Authors:  Girish C Shukla; Richard A Padgett
Journal:  Mol Cell       Date:  2002-05       Impact factor: 17.970

2.  A three-dimensional perspective on exon binding by a group II self-splicing intron.

Authors:  M Costa; F Michel; E Westhof
Journal:  EMBO J       Date:  2000-09-15       Impact factor: 11.598

Review 3.  Emerging clinical applications of RNA.

Authors:  Bruce A Sullenger; Eli Gilboa
Journal:  Nature       Date:  2002-07-11       Impact factor: 49.962

4.  Structure of a self-splicing group II intron catalytic effector domain 5: parallels with spliceosomal U6 RNA.

Authors:  Mahadevan Seetharaman; Nadukkudy V Eldho; Richard A Padgett; Kwaku T Dayie
Journal:  RNA       Date:  2006-02       Impact factor: 4.942

5.  More than one way to splice an RNA: branching without a bulge and splicing without branching in group II introns.

Authors:  V T Chu; Q Liu; M Podar; P S Perlman; A M Pyle
Journal:  RNA       Date:  1998-10       Impact factor: 4.942

6.  Characterization of the branch site in lariat RNAs produced by splicing of mRNA precursors.

Authors:  M M Konarska; P J Grabowski; R A Padgett; P A Sharp
Journal:  Nature       Date:  1985 Feb 14-20       Impact factor: 49.962

7.  Group II intron self-splicing. Alternative reaction conditions yield novel products.

Authors:  K A Jarrell; C L Peebles; R C Dietrich; S L Romiti; P S Perlman
Journal:  J Biol Chem       Date:  1988-03-05       Impact factor: 5.157

8.  NMRPipe: a multidimensional spectral processing system based on UNIX pipes.

Authors:  F Delaglio; S Grzesiek; G W Vuister; G Zhu; J Pfeifer; A Bax
Journal:  J Biomol NMR       Date:  1995-11       Impact factor: 2.835

Review 9.  The spliceosome: the most complex macromolecular machine in the cell?

Authors:  Timothy W Nilsen
Journal:  Bioessays       Date:  2003-12       Impact factor: 4.345

10.  Low-conductivity buffers for high-sensitivity NMR measurements.

Authors:  Alexander E Kelly; Horng D Ou; Richard Withers; Volker Dötsch
Journal:  J Am Chem Soc       Date:  2002-10-09       Impact factor: 15.419

View more
  8 in total

1.  Three essential and conserved regions of the group II intron are proximal to the 5'-splice site.

Authors:  Alexandre de Lencastre; Anna Marie Pyle
Journal:  RNA       Date:  2007-11-26       Impact factor: 4.942

2.  A glimpse into the active site of a group II intron and maybe the spliceosome, too.

Authors:  Kwaku T Dayie; Richard A Padgett
Journal:  RNA       Date:  2008-07-24       Impact factor: 4.942

3.  A dynamic bulge in the U6 RNA internal stem-loop functions in spliceosome assembly and activation.

Authors:  C Joel McManus; Matthew L Schwartz; Samuel E Butcher; David A Brow
Journal:  RNA       Date:  2007-10-09       Impact factor: 4.942

4.  Probing adenine rings and backbone linkages using base specific isotope-edited Raman spectroscopy: application to group II intron ribozyme domain V.

Authors:  Yuanyuan Chen; Nadukkudy V Eldho; T Kwaku Dayie; Paul R Carey
Journal:  Biochemistry       Date:  2010-04-27       Impact factor: 3.162

5.  Site-specific labeling of nucleotides for making RNA for high resolution NMR studies using an E. coli strain disabled in the oxidative pentose phosphate pathway.

Authors:  T Kwaku Dayie; Chandar S Thakur
Journal:  J Biomol NMR       Date:  2010-03-23       Impact factor: 2.835

6.  RNAs synthesized using photocleavable biotinylated nucleotides have dramatically improved catalytic efficiency.

Authors:  Yiling Luo; Nadukkudy V Eldho; Herman O Sintim; T Kwaku Dayie
Journal:  Nucleic Acids Res       Date:  2011-07-08       Impact factor: 16.971

7.  Biomass production of site selective 13C/15N nucleotides using wild type and a transketolase E. coli mutant for labeling RNA for high resolution NMR.

Authors:  Chandar S Thakur; Yiling Luo; Bin Chen; Nadukkudy V Eldho; T Kwaku Dayie
Journal:  J Biomol NMR       Date:  2011-11-29       Impact factor: 2.835

8.  Key labeling technologies to tackle sizeable problems in RNA structural biology.

Authors:  Kwaku T Dayie
Journal:  Int J Mol Sci       Date:  2008-07-14       Impact factor: 6.208

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.